Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

被引：0
|
作者：
Janne B Kjersem
Tone Ikdahl
Tormod Guren
Eva Skovlund
Halfdan Sorbye
Julian Hamfjord
Per Pfeiffer
Bengt Glimelius
Christian Kersten
Hiroko Solvang
Kjell M Tveit
Elin H Kure
机构：
[1] Institute for Cancer Research,Department of Genetics
[2] Oslo University Hospital,Department of Oncology
[3] Oslo University Hospital,School of Pharmacy
[4] University of Oslo and the Norwegian Institute of Public Health,Department of Oncology
[5] Haukeland University Hospital,Department of Oncology
[6] Odense University Hospital,Department of Radiology, Oncology and Radiation Science
[7] Uppsala University,Department of Oncology and Pathology
[8] Karolinska Institutet,Center for Cancer Treatment
[9] Southern Hospital Trust,undefined
来源：
BMC Cancer | / 12卷
关键词：
Colorectal cancer; LCS6; MiRNA polymorphism; Cetuximab; Oxaliplatin; 5-fluorouracil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 37 条
  • [1] Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Kjersem, Janne B.
    Ikdahl, Tone
    Guren, Tormod
    Skovlund, Eva
    Sorbye, Halfdan
    Hamfjord, Julian
    Pfeiffer, Per
    Glimelius, Bengt
    Kersten, Christian
    Solvang, Hiroko
    Tveit, Kjell M.
    Kure, Elin H.
    BMC CANCER, 2012, 12
  • [2] A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
    Saridaki, Zenia
    Weidhaas, Joanne B.
    Lenz, Heinz-Josef
    Laurent-Puig, Pierre
    Jacobs, Bart
    De Schutter, Jef
    De Roock, Wendy
    Salzman, David W.
    Zhang, Wu
    Yang, Dongyun
    Pilati, Camilla
    Bouche, Olivier
    Piessevaux, Hubert
    Tejpar, Sabine
    CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4499 - 4510
  • [3] Let-7 microRNA-binding-site polymorphism in the 3′UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis
    Langevin, Scott M.
    Christensen, Brock C.
    CANCER MEDICINE, 2014, 3 (05): : 1385 - 1395
  • [4] A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy
    Zhang, W.
    Winder, T.
    Ning, Y.
    Pohl, A.
    Yang, D.
    Kahn, M.
    Lurje, G.
    LaBonte, M. J.
    Wilson, P. M.
    Gordon, M. A.
    Hu-Lieskovan, S.
    Mauro, D. J.
    Langer, C.
    Rowinsky, E. K.
    Lenz, H. -J.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 104 - 109
  • [5] Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan
    F Graziano
    E Canestrari
    F Loupakis
    A Ruzzo
    N Galluccio
    D Santini
    M Rocchi
    B Vincenzi
    L Salvatore
    C Cremolini
    C Spoto
    V Catalano
    S D'Emidio
    P Giordani
    G Tonini
    A Falcone
    M Magnani
    The Pharmacogenomics Journal, 2010, 10 : 458 - 464
  • [6] Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
    Graziano, F.
    Canestrari, E.
    Loupakis, F.
    Ruzzo, A.
    Galluccio, N.
    Santini, D.
    Rocchi, M.
    Vincenzi, B.
    Salvatore, L.
    Cremolini, C.
    Spoto, C.
    Catalano, V.
    D'Emidio, S.
    Giordani, P.
    Tonini, G.
    Falcone, A.
    Magnani, M.
    PHARMACOGENOMICS JOURNAL, 2010, 10 (05) : 458 - 464
  • [7] FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Eva Skovlund
    Tone Ikdahl
    Tormod Guren
    Christian Kersten
    Astrid M Dalsgaard
    Mette K Yilmaz
    Tone Fokstuen
    Kjell M Tveit
    Elin H Kure
    BMC Cancer, 14
  • [8] Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin
    Gordon, Michael A.
    Zhang, Wu
    Yang, Dongyun
    El-Khourery, Anthony
    Nagashima, Fumio
    Lurje, Georg
    Labonte, Melissa
    Wilson, Peter
    Sherrod, Andy
    Ladner, Robert D.
    Lenz, Heinz-Josef
    PHARMACOGENOMICS, 2011, 12 (01) : 27 - 39
  • [9] FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin plus /- cetuximab
    Kjersem, Janne B.
    Skovlund, Eva
    Ikdahl, Tone
    Guren, Tormod
    Kersten, Christian
    Dalsgaard, Astrid M.
    Yilmaz, Mette K.
    Fokstuen, Tone
    Tveit, Kjell M.
    Kure, Elin H.
    BMC CANCER, 2014, 14
  • [10] Association of rs712 polymorphism in a let-7 microRNA-binding site of KRAS gene with colorectal cancer in a Mexican population
    Patricia Gallegos-Arreola, Martha
    Moises Zuniga-Gonzalez, Guillermo
    Gomez-Mariscal, Karen
    Alejandra Rosales-Reynoso, Monica
    Figuera, Luis E.
    Maria Puebla-Perez, Ana
    Pineda-Razo, Tomas
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 22 (03) : 324 - 327
1234